Reported Earnings • Mar 15
Third quarter 2026 earnings released: US$0.02 loss per share (vs US$0.33 profit in 3Q 2025) Third quarter 2026 results: US$0.02 loss per share (down from US$0.33 profit in 3Q 2025). Revenue: US$16.6m (down 2.8% from 3Q 2025). Net loss: US$279.0k (down 106% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Duyuru • Mar 06
Champions Oncology, Inc. to Report Q3, 2026 Results on Mar 12, 2026 Champions Oncology, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026 New Risk • Feb 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$80.7m market cap). Reported Earnings • Dec 16
Second quarter 2026 earnings: EPS and revenues exceed analyst expectations Second quarter 2026 results: EPS: US$0.019 (down from US$0.054 in 2Q 2025). Revenue: US$15.0m (up 12% from 2Q 2025). Net income: US$268.0k (down 63% from 2Q 2025). Profit margin: 1.8% (down from 5.4% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.1%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to US$7.80, the stock trades at a trailing P/E ratio of 36.4x. Average trailing P/E is 34x in the Life Sciences industry in the US. Total returns to shareholders of 92% over the past three years. Duyuru • Dec 09
Champions Oncology, Inc. to Report Q2, 2026 Results on Dec 15, 2025 Champions Oncology, Inc. announced that they will report Q2, 2026 results After-Market on Dec 15, 2025 Recent Insider Transactions Derivative • Nov 07
Independent Director exercised options to buy US$636k worth of stock. On the 30th of October, Joel Ackerman exercised options to buy 94k shares at a strike price of around US$2.10, costing a total of US$198k. This transaction amounted to 9.8% of their direct individual holding at the time of the trade. Joel currently holds 962.13k shares (0.06977840319787161 of the company). This was the only transaction from an insider over the last 12 months. Reported Earnings • Sep 16
First quarter 2026 earnings released: US$0.032 loss per share (vs US$0.097 profit in 1Q 2025) First quarter 2026 results: US$0.032 loss per share (down from US$0.097 profit in 1Q 2025). Revenue: US$14.0m (flat on 1Q 2025). Net loss: US$436.0k (down 133% from profit in 1Q 2025). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Sep 15
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to US$8.30, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 29x in the Life Sciences industry in the US. Total loss to shareholders of 9.0% over the past three years. Duyuru • Sep 12
Champions Oncology, Inc. to Report Q1, 2026 Results on Sep 15, 2025 Champions Oncology, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on Sep 15, 2025 Duyuru • Aug 25
Champions Oncology, Inc., Annual General Meeting, Oct 16, 2025 Champions Oncology, Inc., Annual General Meeting, Oct 16, 2025. Location: one university plaza, suite 307, hackensack, newjersey 0760, United States Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$7.62, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 29x in the Life Sciences industry in the US. Total loss to shareholders of 14% over the past three years. Reported Earnings • Jul 25
Full year 2025 earnings released: EPS: US$0.34 (vs US$0.54 loss in FY 2024) Full year 2025 results: EPS: US$0.34 (up from US$0.54 loss in FY 2024). Revenue: US$56.9m (up 14% from FY 2024). Net income: US$4.70m (up US$12.0m from FY 2024). Profit margin: 8.3% (up from net loss in FY 2024). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to US$6.65, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 37x in the Life Sciences industry in the US. Total loss to shareholders of 21% over the past three years. Duyuru • Jul 21
Champions Oncology, Inc. to Report Q4, 2025 Results on Jul 23, 2025 Champions Oncology, Inc. announced that they will report Q4, 2025 results After-Market on Jul 23, 2025 Duyuru • Jul 09
Ch Champions Oncology Launches Radiopharmaceutical Services Platform Champions Oncology announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners. Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems. Champions updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a wide range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to US$8.89, the stock trades at a trailing P/E ratio of 19x. Average trailing P/E is 36x in the Life Sciences industry in the US. Total returns to shareholders of 13% over the past three years. New Risk • Jun 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$94.4m market cap). Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$6.89, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 35x in the Life Sciences industry in the US. Total loss to shareholders of 6.9% over the past three years. Valuation Update With 7 Day Price Move • May 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$6.38, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 38x in the Life Sciences industry in the US. Total loss to shareholders of 14% over the past three years. New Risk • May 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$99.0m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to US$7.49, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 36x in the Life Sciences industry in the US. Total loss to shareholders of 7.5% over the past three years. Reported Earnings • Mar 12
Third quarter 2025 earnings released: EPS: US$0.33 (vs US$0.19 loss in 3Q 2024) Third quarter 2025 results: EPS: US$0.33 (up from US$0.19 loss in 3Q 2024). Revenue: US$17.0m (up 42% from 3Q 2024). Net income: US$4.50m (up US$7.03m from 3Q 2024). Profit margin: 26% (up from net loss in 3Q 2024). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Duyuru • Mar 12
Champions Oncology, Inc. Reaffirms Earnings Guidance for the Year 2025 Champions Oncology, Inc. reaffirmed earnings guidance for the year 2025. The company reaffirmed its full year revenue growth guidance of 10% to 15% and continue to focus on expanding its data business, enhancing profitability and driving shareholder value. Duyuru • Mar 07
Champions Oncology, Inc. to Report Q3, 2025 Results on Mar 11, 2025 Champions Oncology, Inc. announced that they will report Q3, 2025 results After-Market on Mar 11, 2025 Duyuru • Jan 09
Ch Champions Oncology, Inc. Enhances Clinical Bioanalytical Services Portfolio with New Technology Champions Oncology, Inc. announced significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of services will allow Champions to better serve its clients by offering increased depth through higher complexity spectral analysis. Duyuru • Jan 08
Champions Oncology, Inc. Appoints Troy Tremaine to Spearhead Bioanalytical Commercial Strategy Champions Oncology, Inc. announced the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. the company is pleased to welcome Troy Tremaine, who will lead the commercial strategy for this growing business vertical. As a seasoned leader in this field, Troy brings decades of experience in commercial leadership within the preclinical and bioanalytical space, across multiple therapeutic areas. Buy Or Sell Opportunity • Dec 24
Now 22% undervalued Over the last 90 days, the stock has risen 62% to US$7.87. The fair value is estimated to be US$10.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Dec 17
Second quarter 2025 earnings released: EPS: US$0.054 (vs US$0.15 loss in 2Q 2024) Second quarter 2025 results: EPS: US$0.054 (up from US$0.15 loss in 2Q 2024). Revenue: US$13.5m (up 17% from 2Q 2024). Net income: US$728.0k (up US$2.80m from 2Q 2024). Profit margin: 5.4% (up from net loss in 2Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance. Duyuru • Dec 06
Champions Oncology, Inc. to Report Q2, 2025 Results on Dec 11, 2024 Champions Oncology, Inc. announced that they will report Q2, 2025 results After-Market on Dec 11, 2024 Reported Earnings • Sep 12
First quarter 2025 earnings released: EPS: US$0.097 (vs US$0.19 loss in 1Q 2024) First quarter 2025 results: EPS: US$0.097 (up from US$0.19 loss in 1Q 2024). Revenue: US$14.1m (up 12% from 1Q 2024). Net income: US$1.31m (up US$3.88m from 1Q 2024). Profit margin: 9.3% (up from net loss in 1Q 2024). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Duyuru • Sep 10
Champions Oncology, Inc. to Report Q1, 2025 Results on Sep 11, 2024 Champions Oncology, Inc. announced that they will report Q1, 2025 results After-Market on Sep 11, 2024 Duyuru • Aug 28
Champions Oncology, Inc., Annual General Meeting, Oct 14, 2024 Champions Oncology, Inc., Annual General Meeting, Oct 14, 2024. Location: one university plaza, suite 307, hackensack, new jersey 07601, United States Reported Earnings • Jul 19
Full year 2024 earnings released: US$0.54 loss per share (vs US$0.39 loss in FY 2023) Full year 2024 results: US$0.54 loss per share (further deteriorated from US$0.39 loss in FY 2023). Revenue: US$50.2m (down 6.9% from FY 2023). Net loss: US$7.28m (loss widened 36% from FY 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Duyuru • Jul 12
Champions Oncology, Inc. to Report Q4, 2024 Results on Jul 18, 2024 Champions Oncology, Inc. announced that they will report Q4, 2024 results After-Market on Jul 18, 2024 Reported Earnings • Mar 14
Third quarter 2024 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2023) Third quarter 2024 results: US$0.19 loss per share (further deteriorated from US$0.18 loss in 3Q 2023). Revenue: US$12.0m (down 5.9% from 3Q 2023). Net loss: US$2.53m (loss widened 3.7% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Duyuru • Mar 07
Champions Oncology, Inc. to Report Q3, 2024 Results on Mar 12, 2024 Champions Oncology, Inc. announced that they will report Q3, 2024 results After-Market on Mar 12, 2024 New Risk • Dec 22
New major risk - Revenue and earnings growth Earnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 57% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$66.7m market cap). Reported Earnings • Dec 13
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2024 results: US$0.15 loss per share (further deteriorated from US$0.001 loss in 2Q 2023). Revenue: US$11.6m (down 19% from 2Q 2023). Net loss: US$2.07m (loss widened US$2.06m from 2Q 2023). Revenue missed analyst estimates by 9.8%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Duyuru • Dec 05
Champions Oncology, Inc. to Report Q2, 2024 Results on Dec 12, 2023 Champions Oncology, Inc. announced that they will report Q2, 2024 results After-Market on Dec 12, 2023 Duyuru • Oct 18
Champions Oncology, Inc. Appoints Brady Davis as President Champions Oncology, Inc. has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth. Mr. Davis brings more than 25 years of international experience leading medical instrument, software, data, and services companies in the healthcare space. As an executive leader, he has advanced commercial, product/market development, marketing, and bioinformatics teams in both established (Hewlett Packard, Oracle, Illumina) and developing (DNAnexus, Canexia Health) companies. Mr. Davis will be collaborating with the executive team including the commercial and scientific teams to explore strategies to accelerate growth, both organically and in-organically. Recent Insider Transactions • Sep 26
Independent Director recently bought US$97k worth of stock On the 22nd of September, Daniel Mendelson bought around 18k shares on-market at roughly US$5.44 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$147k more in shares than they have sold in the last 12 months. Major Estimate Revision • Sep 23
Consensus EPS estimates upgraded to US$0.49 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.59 to -US$0.495 per share. Revenue forecast steady at US$55.2m. Life Sciences industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$9.50 to US$8.75. Share price rose 2.9% to US$5.40 over the past week. Reported Earnings • Sep 15
First quarter 2024 earnings: EPS and revenues miss analyst expectations First quarter 2024 results: US$0.19 loss per share (further deteriorated from US$0.024 loss in 1Q 2023). Revenue: US$12.6m (down 8.6% from 1Q 2023). Net loss: US$2.57m (loss widened US$2.25m from 1Q 2023). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 90%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. Duyuru • Sep 12
Champions Oncology, Inc. to Report Q1, 2024 Results on Sep 13, 2023 Champions Oncology, Inc. announced that they will report Q1, 2024 results on Sep 13, 2023 Duyuru • Aug 29
Champions Oncology, Inc., Annual General Meeting, Oct 19, 2023 Champions Oncology, Inc., Annual General Meeting, Oct 19, 2023, at 09:00 US Eastern Standard Time. Location: the Company’s headquarters, located at One University Plaza, Suite 307, Hackensack, New Jersey 07601 New Jersey United States Agenda: To discuss elect the seven board of director nominees named in the accompanying proxy statement to the board of directors for the ensuring year and until his successor has been elected and qualified, or until his earlier death, resignation or removal; to discuss ratify the appointment of eisneramper llp as our independent registered public accounting firm for the fiscal year ending april 30, 2024; to approve a non-binding advisory resolution relating to the compensation of our named executive officers; and to discuss transact such other business. New Risk • Jul 26
New major risk - Revenue and earnings growth Earnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$86.3m market cap). Reported Earnings • Jul 25
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: US$0.39 loss per share (down from US$0.042 profit in FY 2022). Revenue: US$53.9m (up 9.7% from FY 2022). Net loss: US$5.34m (down US$5.88m from profit in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Duyuru • Jul 23
Champions Oncology, Inc. to Report Q4, 2023 Results on Jul 24, 2023 Champions Oncology, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Jul 24, 2023 New Risk • Jun 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$64k net loss next year). Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (US$82.0m market cap). Reported Earnings • Mar 17
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: US$0.18 loss per share (down from US$0.058 profit in 3Q 2022). Revenue: US$12.8m (down 3.2% from 3Q 2022). Net loss: US$2.44m (down 410% from profit in 3Q 2022). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Major Estimate Revision • Jan 21
Consensus EPS estimates fall by 33% The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from US$56.6m to US$54.7m. Losses expected to increase from US$0.06 per share to US$0.08. Life Sciences industry in the US expected to see average net income growth of 4.2% next year. Consensus price target down from US$13.67 to US$11.67. Share price fell 5.1% to US$4.08 over the past week. Major Estimate Revision • Dec 22
Consensus EPS estimates have been downgraded. The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from US$58.1m to US$56.6m. Now expected to report a loss of US$0.06 per share instead of US$0.15 per share profit previously forecast. Life Sciences industry in the US expected to see average net income growth of 3.3% next year. Consensus price target of US$13.67 unchanged from last update. Share price rose 3.3% to US$4.75 over the past week. Price Target Changed • Dec 14
Price target decreased to US$13.67 Down from US$15.67, the current price target is an average from 3 analysts. New target price is 197% above last closing price of US$4.60. Stock is down 41% over the past year. The company is forecast to post earnings per share of US$0.15 for next year compared to US$0.042 last year. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 5 highly experienced directors. Independent Director Rob Brainin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Sep 22
Consensus EPS estimates increase by 100% The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from US$58.0m to US$59.8m. EPS estimate increased from US$0.08 to US$0.15 per share. Net income forecast to grow 534% next year vs 5.9% growth forecast for Life Sciences industry in the US. Consensus price target down from US$15.67 to US$15.33. Share price fell 5.9% to US$8.23 over the past week. Major Estimate Revision • Aug 02
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 EPS estimate increased from US$0.18 to US$0.20. Revenue forecast steady at US$58.0m. Net income forecast to grow 430% next year vs 6.6% growth forecast for Life Sciences industry in the US. Consensus price target up from US$14.67 to US$15.67. Share price was steady at US$8.70 over the past week. Reported Earnings • Jul 22
Full year 2022 earnings released: EPS: US$0.042 (vs US$0.028 in FY 2021) Full year 2022 results: EPS: US$0.042 (up from US$0.028 in FY 2021). Revenue: US$49.1m (up 20% from FY 2021). Net income: US$548.0k (up 51% from FY 2021). Profit margin: 1.1% (up from 0.9% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 16%, compared to a 5.7% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 5 highly experienced directors. Independent Director Rob Brainin was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Mar 22
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from US$0.07 to US$0.09. Revenue forecast steady at US$48.8m. Net income forecast to grow 1,117% next year vs 8.8% growth forecast for Life Sciences industry in the US. Consensus price target of US$15.67 unchanged from last update. Share price rose 6.4% to US$8.46 over the past week. Reported Earnings • Mar 18
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: US$0.058 (down from US$0.072 in 3Q 2021). Revenue: US$13.2m (up 22% from 3Q 2021). Net income: US$787.0k (down 18% from 3Q 2021). Profit margin: 6.0% (down from 8.9% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.8%. Earnings per share (EPS) also surpassed analyst estimates by 100%. Over the next year, revenue is forecast to grow 17%, compared to a 8.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 15
First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.006 profit in 1Q 2021) The company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$11.3m (up 18% from 1Q 2021). Net loss: US$172.0k (down 329% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Reported Earnings • Jul 24
Full year 2021 earnings released: EPS US$0.025 (vs US$0.17 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$41.0m (up 28% from FY 2020). Net income: US$334.0k (up US$2.31m from FY 2020). Profit margin: 0.8% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Price Target Changed • Mar 16
Price target increased to US$15.00 Up from US$13.83, the current price target is an average from 3 analysts. New target price is 9.4% above last closing price of US$13.71. Stock is up 180% over the past year. Analyst Estimate Surprise Post Earnings • Mar 14
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) also surpassed analyst estimates by 400%. Over the next year, revenue is forecast to grow 17%, compared to a 71% growth forecast for the Life Sciences industry in the US. Reported Earnings • Mar 13
Third quarter 2021 earnings released: EPS US$0.055 (vs US$0.035 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$10.8m (up 20% from 3Q 2020). Net income: US$740.0k (up 82% from 3Q 2020). Profit margin: 6.8% (up from 4.5% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Mar 03
New 90-day high: US$12.21 The company is up 12% from its price of US$10.90 on 02 December 2020. The American market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$19.62 per share. Executive Departure • Feb 16
Independent Director has left the company On the 8th of February, Abba Poliakoff's tenure as Independent Director ended after 13.0 years in the role. As of December 2020, Abba personally held 60.15k shares (US$649k worth at the time). Abba is the only executive to leave the company over the last 12 months. Recent Insider Transactions • Dec 18
Board Member recently sold US$357k worth of stock On the 16th of December, Philip Breitfeld sold around 31k shares on-market at roughly US$11.35 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$349k more than they bought in the last 12 months. Price Target Changed • Dec 16
Price target raised to US$12.83 Up from US$11.00, the current price target is an average from 3 analysts. The new target price is 13% above the current share price of US$11.40. As of last close, the stock is up 49% over the past year. Is New 90 Day High Low • Nov 11
New 90-day high: US$9.99 The company is up 6.0% from its price of US$9.44 on 13 August 2020. The American market is also up 6.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Life Sciences industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$12.24 per share. 
